Evidence map›Paper›PMID 42706179›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026

[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].

H Zhang, X Y He, X Xiao, H R Lyu, M F Zhao

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

H ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China.
X Y HeDepartment of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China.
X XiaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China.
H R LyuDepartment of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China.
M F ZhaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after failure of chimeric antigen receptor T (CAR-T) cell therapy. Nine patients with R/R DLBCL who failed CAR-T therapy and received glofitamab combined with polatuzumab vedotin treatment at the Hematology Department of Tianjin First Central Hospital from March 2024 to April 2025 were selected for retrospective analysis of their clinical data. The overall response rate was 77.8%, and the complete response rate was 55.6% following six cycles of treatment. The median follow-up period was 12 (5-18) months. The 1-year progression-free survival rate and overall survival rate were 71.1% (95%

Indexed as

Antibodies, BispecificAntibodies, MonoclonalLymphoma, Large B-Cell, DiffuseFemaleHumansImmunoconjugatesImmunotherapy, AdoptiveMaleMiddle AgedRetrospective StudiesAntibodies, BispecificAntibodies, MonoclonalImmunoconjugatespolatuzumab vedotin

Identifiers

PMID42706179
PMCPMC13575533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.